Skip to main content

The LLS Blog

Read about survivors, research, fundraising and advocacy.

Take Part in the Raise Hope, End Cancer Fundraiser with Walgreens

Walgreens, The Leukemia & Lymphoma Society (LLS), and Susan G. Komen (Komen) are collaborating to raise funds to enable new research in breast and blood cancers and expand access, treatment, and support services for those living with these diseases. In 2019, Walgreens pledged to contribute more than $25 million to LLS and Komen collectively over the next five years to improve the health and well-being of people living with cancer nationwide. But we can’t do this alone.

LLS Celebrates New Drug Approval for a Rare Form of Childhood Cancer

At The Leukemia & Lymphoma Society (LLS), we celebrate every advancement toward our mission of curing blood cancer and improving the quality of life for patients and their families. Today’s reason to celebrate is the news that the U.S. Food and Drug Administration (FDA) has approved a new treatment for children with a rare type of cancer called ALK-positive anaplastic large cell lymphoma (ALCL).

Practicing Self-Advocacy During My PTCL Journey

The LLS Blog invites Aaron, who was diagnosed with peripheral T-cell lymphoma (PTCL), to share his reflections on becoming a self-advocate throughout his cancer experience. Read his powerful first-hand account

A New Mom’s Determination to Fight Cancer During a Global Pandemic

Lisa’s world was turned upside-down when she was diagnosed with a rare subtype of lymphoma called nodular lymphocyte predominant Hodgkin lymphoma (NLPHL), which is a type of blood cancer that develops in the lymphatic system. She was immediately admitted to the hospital after her diagnosis to undergo intense treatment, and had to say goodbye to her newborn daughter Quinn, unsure of whether or not she’d ever see her again.

Precision Medicine and Combination Therapies #ASH20

The more we learn more about the underlying mutations that drive cancer the better we get at more precisely hitting those targets with specialized, less toxic treatments. We now understand that a one-size-fits all approach to treating cancer is ineffective for many patients. As The 62nd American Society of Hematology (ASH) annual Meeting ends, let’s take a look at results from studies of targeted therapies that work by interfering with the altered genes that cause cancer cells to grow and spread. Much of the work stems from research supported by LLS.

Older Posts